Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

Giuseppe Salemi, Paolo Ragonese, Giovanna Borriello, Giusi Graziano, Salvatore Cottone, Renato Docimo, Emanuele D’Amico, Paola Valentino, Antonio Gallo, Aurora Zanghì, Roberto Bruno Bossio, Giuseppe Salemi, Maria Buccafusca, Paola Valentino, Paolo Ragonese, Mario Zappia, Carlo Pozzilli, Luigi Maria Edoardo Grimaldi, Francesco Patti, Gioacchino TedeschiGraziella Callari

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

BACKGROUND:The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment.METHODS:A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs.RESULTS:Of the 587 pwRRMS treated with DMF and the 316 pwRRMS treated with TRF, 468 pwRRMS were successfully paired by propensity score: 234 on DMF and 234 on TRF. The percentages of pwRRMS who achieved NEDA 3 were 80.3% in the DMF group and 77.2% in the TRF group. Serious adverse events occurred in four (1.9%) pwRRMS on DMF and in three (1.3%) pwRRMS on TRF.CONCLUSIONS:DMF and TRF significantly impacted RRMS disease activity in our study. Serious safety concerns were recorded in less than 2% of the studied population.
Lingua originaleEnglish
pagine (da-a)1-14
Numero di pagine14
RivistaTherapeutic Advances in Neurological Disorders
Volume11
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Neurology
  • Clinical Neurology

Fingerprint Entra nei temi di ricerca di 'Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience'. Insieme formano una fingerprint unica.

Cita questo